Concord Biotech Profit & Loss Annual

BSE: 543960 | NSE: CONCORDBIO | ISIN: INE338H01029 | Sector: Biotechnology & Drugs

1,468.25 -38.40 (-2.55%)Updated : 15 Sep 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	761.75	745.17	638.90	562.07
Other Net	9.25	9.60	10.05	14.51
Diluted Weighted Average Shares	10.46	10.46	10.46	10.46
Gain( Loss)on Saleof Assets	0.01	-0.22	0.01	-0.09
Depreciation/ Amortization	74.46	54.37	53.59	54.03
Operating Income	293.14	454.92	378.04	291.10
Net Income	260.91	371.64	308.10	240.09
Income Availableto Com Excl Extra Ord	260.91	371.64	308.10	240.09
Other Operating Expenses Total	11.66	9.08	7.94	4.97
Net Income Before Taxes	344.65	494.55	412.56	322.01
Minority Interest	1.68	-	-	-
Net Income After Taxes	259.23	371.64	308.10	240.09
Income Availableto Com Incl Extra Ord	260.91	371.64	308.10	240.09
Costof Revenue Total	361.87	417.74	334.17	277.86
Gross Profit	693.02	782.34	682.77	575.31
Interest Inc( Exp) Net- Non- Op Total	42.24	30.26	24.46	16.50
Unusual Expense( Income)	3.28	-	0.00	0.03
Diluted Net Income	260.91	371.64	308.10	240.09
DPS- Common Stock Primary Issue	7.55	10.70	8.75	-
Provisionfor Income Taxes	85.42	122.91	104.46	81.93
period Type	-	-	-	-
Net Income Before Extra Items	260.91	371.64	308.10	240.09
Total Revenue	1,054.89	1,200.09	1,016.94	853.17
period Length	12.00	12.00	12.00	12.00
Revenue	1,054.89	1,200.09	1,016.94	853.17
Selling/ General/ Admin Expenses Total	310.49	263.98	243.19	225.17
Diluted Normalized EPS	25.17	35.54	29.45	22.96
Diluted EPS Excluding Extra Ord Items	24.94	35.52	29.45	22.95

*All figures in crores except per share values

272.00+6.05(2.27%)

1,260.00+20.50(1.65%)

11,053.00+157.00(1.44%)

1,196.80-29.75 (-2.43%)

185.95-2.60 (-1.38%)

Related News